Andrew Rae, MBA
Andrew’s ‘deal sheet’ includes partnerships with AstraZeneca, Ionis Pharmaceuticals, Alexion Pharmaceuticals, and Juvenile Diabetes Research Foundation.
His degrees include an Honours BSc. from Western and an MBA from Simon Fraser University. Over the past two decades Andrew has held roles of increasing responsibility as a senior biotechnology executive (including CEO, CFO and VP roles) and has held multiple board roles.
Recognition as a CEO in the biopharmaceutical industry has included a BIOTECanada Gold Leaf Award for Early Stage Company of the Year, Pacific Finalist – Ernst & Young Entrepreneur of the Year (Canada), and the TSX Venture 50 Award (Top Company Technology & Life Sciences).
Prior to his operational experiences, Andrew served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada).